SwitzerlandSwitzerland

Debiopharm licences potential Hepatitis C blockbuster to Novartis

10.02.2010

Lausanne – Swiss Debiopharm Group has signed an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of 1st oligopeptide Debio 025 (alisporivir). The first-in-class cyclophilin inhibitor, which is currently undergoing clinical proof-of-principal studies as treatment against Hepatitis C, will be marketed world-wide by Novartis with the exception of Japan. The upfront payment made for the drug is unknown, but Novartis said that Debiopharm will receive development and sales milestones as well as royalties. According to Debiopharm data, only 20% of the 170 million people who suffer from HCV, are currently treated adequately. Debio025 has some chemical features in common with cyclosporine A, but has none of its immunosuppressive effects. In phase I and IIa trials, Debiopharm stated that it showed a strong inhibitory effect on replication of 4 HCV subtypes as a monotherapy as well as in combination with peg-IFN-alpha-2a.

SwitzerlandSwitzerland

30.03.2012

Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...

SwitzerlandSwitzerland

27.03.2012

London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...

SwitzerlandSwitzerland

26.03.2012

Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...

SwitzerlandSwitzerland

09.03.2012

After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...

SwitzerlandSwitzerland

08.03.2012

The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...

SwitzerlandSwitzerland

06.03.2012

Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...

SwitzerlandSwitzerland

06.03.2012

Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....

SwitzerlandSwitzerland

05.03.2012

Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-switzerland/article/debiopharm-licences-potential-hepatitis-c-blockbuster-to-novartis.html

Product of the week

Products

Events

All Events

Current issue

All issues